Disposition of eslicarbazepine acetate in the mouse after oral administration

Fundamental & Clinical Pharmacology
Gilberto AlvesPatrício Soares-da-Silva

Abstract

Eslicarbazepine acetate is a promising antiepileptic drug structurally related to carbamazepine and oxcarbazepine, which is in the final phase of clinical development. The metabolism of eslicarbazepine acetate is clearly species dependent and, in this case, among small laboratory animals, the mouse seems to be the most relevant species to humans. Hence, the aim of this study was to investigate the plasma, brain and liver disposition of eslicarbazepine acetate in mice to better understand its disposition in humans. Adult male CD-1 mice were treated orally with a single dose of eslicarbazepine acetate 350 mg/kg. Blood samples, brain and liver tissues were taken at 0.25, 0.5, 0.75, 1, 2, 4, 6, 10, 16 and 24 h post-dose. Plasma and tissue levels of eslicarbazepine acetate and its metabolites (S-licarbazepine, R-licarbazepine and oxcarbazepine) were assessed by using high-performance liquid chromatography-ultraviolet detection. Both eslicarbazepine acetate and R-licarbazepine concentrations were below the limit of quantification of the assay in all matrices. Eslicarbazepine acetate was rapidly and extensively metabolized to S-licarbazepine (major metabolite), which was oxidized to oxcarbazepine to a small extent. The brain/plasma ra...Continue Reading

References

Jan 1, 1994·Epilepsia·M J McLeanK F Feldmann
Jul 6, 2000·Archives of Medical Research·D F González-EsquivelH Jung-Cook
Apr 12, 2002·Seizure : the Journal of the British Epilepsy Association·Patrick Kwan, Martin J Brodie
Sep 10, 2003·Clinical Pharmacokinetics·Theodor W MayBernhard Rambeck
Nov 25, 2003·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Csilla Misl'anová, Milan Hutta
Jan 27, 2004·Seizure : the Journal of the British Epilepsy Association·M J McEwanJulie Metcalfe
Mar 31, 2005·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·C ArellanoG Houin
Jul 5, 2005·Drugs in R&D·Joana MaiaPatricio Soares-da-Silva
Jul 5, 2005·Expert Opinion on Investigational Drugs·S C Schachter
Aug 16, 2005·Journal of Clinical Pharmacology·Luis AlmeidaPatrício Soares-da-Silva
Oct 26, 2005·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·C ArellanoG Houin
Dec 3, 2005·BMJ : British Medical Journal·Martin J Brodie, Patrick Kwan
May 31, 2006·Expert Opinion on Investigational Drugs·Meir Bialer
Dec 13, 2006·Seizure : the Journal of the British Epilepsy Association·Alla B GuekhtEugeny I Gusev
Jan 3, 2007·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Luis Almeida, Patrício Soares-da-Silva
May 23, 2007·Clinical Drug Investigation·Gérard Flesch
Feb 2, 2008·Journal of Pharmaceutical Sciences·Jun ShenClinton F Stewart

❮ Previous
Next ❯

Citations

Mar 22, 2012·Medicinal Research Reviews·Patrick Vlieghe, Michel Khrestchatisky
Nov 1, 2011·Drugs·Cinzia Fattore, Emilio Perucca

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.